BioAge Lawsuit Submission Form

Company: BioAge Labs, Inc.

Ticker: (NASDAQ) BIOA

Deadline

Passed

Lead Plaintiff Deadline: March 10, 2025

Never Miss Another Deadline

Choose your preferred way to stay informed of new case launches and settlement deadlines.

Scan the QR code or click the button to join.

Join on WhatsApp

Get Updates by Email

Subscribe for email notifications.

Full Name

No spam, opt-out anytime, alert list is free.

Allegations

According to the complaint, on December 6, 2024, BioAge announced that it would discontinue the ongoing STRIDES Phase 2 trial for azelaprag, its lead product candidate, citing safety concerns over elevated liver transaminase levels in participants. This came as a surprise because, at the time of its IPO less than three months earlier, BioAge highlighted azelaprag's potential in patients undergoing obesity therapy with incretin drugs. Following this news, BioAge’s stock price declined from $20.09 per share on December 6, 2024 to $4.65 per share on December 7, 2024.